iCareBreast+: a smartphone self-care app for women with breast cancer on chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This two-group pilot randomized controlled trial will recruit 40 women with stage 1–3 breast cancer undergoing chemotherapy at the National Cancer Centre Singapore and randomly assign them to receive routine care plus the iCareBreast+ app or routine care alone. The app was refined using comprehensive assessments of patient needs and includes self-care content, psychosocial support resources, and interactive features delivered over a 2-month period. Feasibility and acceptability outcomes (recruitment, attrition, usability, perceived usefulness, and app quality) will be collected alongside validated measures of self-efficacy, knowledge of treatment, anxiety, depression, health-related quality of life, social support and satisfaction with oncologic care at baseline and after the intervention. This pilot will provide preliminary effect size estimates to inform a larger definitive trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Women who:

* are the age of 21 years old and above at the point of recruitment;
* are diagnosed with stage 1-3 breast cancer;
* will undergo chemotherapy first time (initiating or up to #4 cycles of chemo is acceptable);
* can speak, read and write in English or Mandarin; and
* has access to and able to use smart phone.

Exclusion Criteria:

Those who :

* are with a history of or concurrent other cancer types;
* have been suffering from psychiatric illness (e.g., schizophrenia), anxiety disorder or other mood disorder or impaired cognitive function;
* have alcohol or substance abuse within the previous year;
* are undergoing concurrent psychosocial interventions; and
* have been in the bereavement period in the last 6 months
* are in their pregnancy.

Where it's running

• National Cancer Centre, Singapore
  Singapore, Singapore Recruiting

Study contacts

• Principal investigator: Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed — National Cancer Centre, Singapore
• Study coordinator: Dr Ryan Shea YC Tan, MBBS, MRCP(UK), MMed
• Email: ryan.shea.tan.y.c@singhealth.com.sg
• Phone: +65 64368000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.